Literature DB >> 26412572

Gamma-radiolytic stability of new methylated TODGA derivatives for minor actinide recycling.

Hitos Galán1, Christopher A Zarzana, Andreas Wilden, Ana Núñez, Holger Schmidt, Richard J M Egberink, Andrea Leoncini, Joaquín Cobos, Willem Verboom, Giuseppe Modolo, Gary S Groenewold, Bruce J Mincher.   

Abstract

The stability against gamma radiation of MeTODGA (methyl tetraoctyldiglycolamide) and Me2TODGA (dimethyl tetraoctyldiglycolamide), derivatives from the well-known extractant TODGA (N,N,N',N'-tetraoctyldiglycolamide), were studied and compared. Solutions of MeTODGA and Me2TODGA in alkane diluents were subjected to (60)Co γ-irradiation in the presence and absence of nitric acid and analyzed using LC-MS to determine their rates of radiolytic concentration decrease, as well as to identify radiolysis products. The results of product identification from three different laboratories are compared and found to be in good agreement. The diglycolamide (DGA) concentrations decreased exponentially with increasing absorbed dose. The MeTODGA degradation rate constants (dose constants) were uninfluenced by the presence of nitric acid, but the acid increased the rate of degradation for Me2TODGA. The degradation products formed by irradiation are also initially produced in greater amounts in acid-contacted solution, but products may also be degraded by continued radiolysis. The identified radiolysis products suggest that the weakest bonds are those in the diglycolamide center of these molecules.

Entities:  

Year:  2015        PMID: 26412572     DOI: 10.1039/c5dt02484f

Source DB:  PubMed          Journal:  Dalton Trans        ISSN: 1477-9226            Impact factor:   4.390


  1 in total

1.  Gamma radiolytic stability of the novel modified diglycolamide 2,2'-oxybis(N,N-didecylpropanamide) (mTDDGA) for grouped actinide extraction.

Authors:  Bart Verlinden; Karen Van Hecke; Andreas Wilden; Michelle Hupert; Beatrix Santiago-Schübel; Richard J M Egberink; Willem Verboom; Piotr M Kowalski; Giuseppe Modolo; Marc Verwerft; Koen Binnemans; Thomas Cardinaels
Journal:  RSC Adv       Date:  2022-04-25       Impact factor: 3.361

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.